MCID: MLG079
MIFTS: 42

Malignant Pleural Mesothelioma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 36 15 17 71
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 54

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
KEGG 36 H00015
NCIt 49 C7376
SNOMED-CT 67 254645002
ICD10 32 C45.0
UMLS 71 C0812413

Summaries for Malignant Pleural Mesothelioma

KEGG : 36 Malignant mesothelioma (MM) is a rare but very aggressive tumor that arises from mesothelial cells lining the pleural, peritoneal and pericardial cavities. Malignant pleural mesothelioma (MPM) is the most common type, accounting for about 70% of all MM cases. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The accumulation of numerous clonal chromosomal deletions in most MMs suggests a multistep process of tumorigenesis, characterized by the loss and/or inactivation of multiple tumor suppressor genes (TSGs). Cytogenetic and loss of heterozygosity (LOH) analyses of MMs have demonstrated frequent deletions of specific sites within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q, and 22q. Furthermore, TSGs within two of these regions, i.e., p16/CDKN2A-p14ARF at 9p21 and NF2 at 22q12, are frequently altered in MMs. Mutations of the p53 gene (TP53) are occasionally observed in MMs.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to benign mesothelioma and mesothelioma, malignant, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Malignant Pleural Mesothelioma is GAS5 (Growth Arrest Specific 5), and among its related pathways/superpathways is Adhesion. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes.

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 benign mesothelioma 33.2 WT1 THBD CALB2
2 mesothelioma, malignant 32.4 WT1 TYMS THBD SPP1 NKX2-1 MUC1
3 pleural disease 31.9 MSLN MIR625 CALB2
4 pneumothorax 31.6 NKX2-1 MUC1 CALB2
5 asbestosis 31.4 WT1 THBD MUC1 MSLN CALB2
6 small cell carcinoma 31.3 WT1 NKX2-1 MUC1
7 malignant peritoneal mesothelioma 31.2 MUC1 BIRC5
8 sarcomatoid mesothelioma 31.1 WT1 THBD NKX2-1 MUC1 MSLN CALB2
9 peritoneal mesothelioma 31.1 WT1 THBD MUC1 CALB2
10 wilms tumor 1 30.9 WT1 CDH2 CALB2 BIRC5
11 pleural cancer 30.9 WT1 TYMS SPP1 MSLN MIR625 CALB2
12 pericardial mesothelioma 30.8 MUC1 CALB2
13 rhabdoid tumor predisposition syndrome 1 30.7 WT1 SPP1 MUC1
14 thymic carcinoma 30.7 NKX2-1 MUC1 CALB2
15 sarcoma, synovial 30.7 WT1 MUC1 CALB2
16 carcinosarcoma 30.7 WT1 MUC1 CALB2
17 osteogenic sarcoma 30.6 WT1 SPP1 PVT1 GAS5
18 pancreatic adenocarcinoma 30.6 SPP1 MUC1 MSLN CDH2 BIRC5
19 colorectal adenocarcinoma 30.5 TYMS NKX2-1 MUC1
20 clear cell renal cell carcinoma 30.3 WT1 PVT1 MUC1 CALB2 BIRC5
21 lung cancer susceptibility 3 30.3 THBD SPP1 NKX2-1 MUC1 MSLN MIR625
22 ovarian cancer 29.6 WT1 TYMS SPP1 PVT1 MUC1 MSLN
23 renal cell carcinoma, nonpapillary 29.5 WT1 SPP1 PVT1 NKX2-1 MUC1 MSLN
24 pancreatic cancer 29.4 TYMS PVT1 MUC1 MSLN GAS5 ENSG00000261211
25 gastric cancer 28.6 TYMS SNHG8 SNHG7 PVT1 MUC1 GAS5
26 neutropenia 10.8
27 rare tumor 10.7
28 adenocarcinoma 10.7
29 childhood malignant schwannoma 10.7 SPP1 BIRC5
30 asbestos intoxication 10.7
31 fallopian tube carcinosarcoma 10.6 WT1 CALB2
32 rete testis neoplasm 10.6 NKX2-1 CALB2
33 rete testis adenocarcinoma 10.6 NKX2-1 CALB2
34 epididymal neoplasm 10.6 WT1 CALB2
35 spindle cell thymoma 10.6 MUC1 CALB2
36 lung sarcoma 10.6 NKX2-1 CALB2
37 wolffian duct adenocarcinoma 10.6 WT1 CALB2
38 testicular fibroma 10.6 WT1 CALB2
39 ovarian germ cell teratoma 10.6 NKX2-1 CALB2
40 juvenile type testicular granulosa cell tumor 10.6 WT1 CALB2
41 testicular granulosa cell tumor 10.6 WT1 CALB2
42 bile duct mucoepidermoid carcinoma 10.6 TYMS MUC1
43 liver leiomyosarcoma 10.6 WT1 CALB2
44 ovarian endometrioid stromal sarcoma 10.6 WT1 CALB2
45 malignant epithelial mesothelioma 10.6 THBD CALB2
46 ovarian gonadoblastoma 10.6 WT1 CALB2
47 pericardium cancer 10.6 WT1 MSLN CALB2
48 lung cancer 10.6
49 thymus clear cell carcinoma 10.6 NKX2-1 CALB2
50 peritoneum cancer 10.6 WT1 MSLN CALB2

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


fatigue, dyspnea, chest pain, chills, malaise

Drugs & Therapeutics for Malignant Pleural Mesothelioma

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
6
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
7
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
Pembrolizumab Approved Phase 3 1374853-91-4
10
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
11
Gemcitabine Approved Phase 3 95058-81-4 60750
12
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
15
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
16
Durvalumab Approved, Investigational Phase 3 1428935-60-7
17
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
18
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
21
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
22 Antiemetics Phase 3
23
Liposomal doxorubicin Phase 3 31703
24 Mitomycins Phase 3
25 Vitamins Phase 2, Phase 3
26 Vitamin B 12 Phase 2, Phase 3
27 Vitamin B12 Phase 2, Phase 3
28 Mitogens Phase 3
29 Endothelial Growth Factors Phase 3
30 interferons Phase 3
31 Interferon-alpha Phase 3
32 Angiogenesis Inhibitors Phase 3
33 Interferon alpha-2 Phase 3
34 Tin Fluorides Phase 3
35 Immunosuppressive Agents Phase 3
36 Immunologic Factors Phase 3
37 Antibodies, Monoclonal Phase 3
38 Tubulin Modulators Phase 3
39 Antimitotic Agents Phase 3
40 Anti-Infective Agents Phase 3
41 Antiviral Agents Phase 3
42 Antimetabolites Phase 3
43 Vinca Alkaloids Phase 3
44 Antineoplastic Agents, Immunological Phase 3
45 Antibodies Phase 3
46 Immunoglobulins Phase 3
47 Vitamin B Complex Phase 3
48 Folic Acid Antagonists Phase 3
49 Folate Phase 3
50 Vitamin B9 Phase 3

Interventional clinical trials:

(show top 50) (show all 192)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
2 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 vorinostat;Placebo
3 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
5 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
6 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
7 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
9 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
10 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
11 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
12 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
13 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
14 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Not yet recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
15 DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial Not yet recruiting NCT04334759 Phase 3 Durvalumab;Standard Chemotherapy
16 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
17 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
18 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
19 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
20 Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
21 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
22 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
23 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
24 A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma Unknown status NCT02303899 Phase 2 Gemcitabine;Imatinib mesylate
25 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
26 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
27 Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy Unknown status NCT02049060 Phase 1, Phase 2 Tivantinib
28 Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) Completed NCT00770120 Phase 2 everolimus
29 A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM)) Completed NCT01112293 Phase 2 GC1008
30 Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
31 Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
32 NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen Completed NCT00484276 Phase 2 NGR-hTNF
33 Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
34 A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma Completed NCT01590160 Phase 1, Phase 2 Ganetespib
35 A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma Completed NCT02347917 Phase 1, Phase 2 BBI608;Pemetrexed;Cisplatin
36 A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
37 An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
38 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
39 NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01358084 Phase 2 NGR-hTNF;Placebo
40 A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study Completed NCT02497508 Phase 2 nivolumab
41 A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
42 A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma Completed NCT00243074 Phase 2 cediranib maleate
43 Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
44 Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
45 Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
46 A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy Completed NCT02610140 Phase 2 Anetumab ravtansine (BAY 94-9343);Vinorelbine
47 A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
48 Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00365053 Phase 2 belinostat
49 Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2 liposomal NDDP
50 A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma Completed NCT00039182 Phase 2 erlotinib hydrochloride

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

40
Lung, T Cells, Testes, Lymph Node, Endothelial, Brain, Breast

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 3850)
# Title Authors PMID Year
1
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. 54 61
20177021 2010
2
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. 54 61
20075387 2010
3
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. 61 54
19302997 2009
4
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. 61 54
19528482 2009
5
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. 54 61
19201924 2009
6
Osteopontin is not a specific marker in malignant pleural mesothelioma. 61 54
19634115 2009
7
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. 61 54
19516197 2009
8
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. 61 54
18827603 2008
9
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. 61 54
18394747 2008
10
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. 54 61
18670302 2008
11
Prognostic role of osteopontin expression in malignant pleural mesothelioma. 61 54
18550471 2008
12
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. 61 54
18422869 2008
13
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report]. 61 54
18051806 2007
14
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. 54 61
17646232 2007
15
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. 54 61
17671130 2007
16
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. 54 61
17290392 2007
17
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. 54 61
17504993 2007
18
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. 54 61
17493236 2007
19
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. 54 61
17279584 2007
20
Molecular basis of antifolate resistance. 61 54
17333344 2007
21
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. 61 54
16294031 2006
22
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. 54 61
15447976 2005
23
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. 54 61
12940775 2003
24
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. 54 61
12800189 2003
25
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. 54 61
12479365 2002
26
Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. 54 61
11956641 2002
27
Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. 54 61
11307155 2001
28
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma. 54 61
10737384 2000
29
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. 61 54
9639123 1998
30
Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. 61 54
9533946 1998
31
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. 54 61
9692834 1998
32
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. 61 54
1357974 1992
33
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful? 61
32002813 2020
34
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful? 61
31512057 2020
35
Non-incisional pleurectomy/decortication. 61
32011679 2020
36
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy. 61
32312091 2020
37
Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma. 61
32057688 2020
38
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma. 61
31634442 2020
39
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. 61
32249197 2020
40
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. 61
32448904 2020
41
Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma. 61
32542810 2020
42
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. 61
32516245 2020
43
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. 61
32179179 2020
44
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. 61
32532926 2020
45
Fibrolipoma of the left ventricle: an uncommon incidental autopsy finding. 61
31776801 2020
46
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). 61
31872928 2020
47
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. 61
32081346 2020
48
Preoperative prediction of unresectability in malignant pleural mesothelioma. 61
32087959 2020
49
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. 61
32330840 2020
50
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma. 61
32562788 2020

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 MUC1 MSLN CDH2

GO Terms for Malignant Pleural Mesothelioma

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....